Are biosimilars interchangeable? – A discussion on efficacy and safety profile with practical tips from experts

Do biosimilars have the same safety and efficacy profile as the reference products? How are biosimilars developed? Are they interchangeable? Can adoption provide a significant cost saving? If you have similar questions, this is the session you must attend. Dr. Kevin Fernando will look at the history of the development and evidence base for biosimilars. Su Down will explore in detail the use of biosimilars in practice.

Learning outcomes:

  • Learn the requirements for approval and licensing of biosimilar drugs
  • Identify if there are differences in efficacy and safety between biosimilars and originator products and why we should use biosimilars in practice
  • Ideal candidates to start or switch to a biosimilar insulin
  • Understand the approach to switching, including whether dose changes are required

*This session is organised and remunerated by Mylan

Tuesday 29 October 2019

16:10 - 17:00

Primary, Community & Specialist Care

MDT Icon Blue


Susan Down
Nurse Consultant Diabetes, Somerset Primary Care Trust and Yeovil District Hospital NHS Foundation Trust
GP Partner & Medical Education & Scottish Lead, North Berwick Health Centre, GPwSI Diabetes, Primary Care Diabetes Society